ERBB2 and breast cancer: In breast cancer, a high frequency of TILs is associated with poorer survival in patients with ER+ and Her2+ breast tumor (56), while in TNBCs, the most aggressive and immunogenic subtype (140–142), the high incidence of TILs is significantly associated with longer survival (79, 143–145), indicating that the mere presence of TILs is insufficient to precisely predict their influence, and disease progression and clinical outcomes are influenced by TIL subtypes and their biological and functional characteristics rather than their density (146).